by Raynovich Rod | May 1, 2017 | Biopharmaceuticals
Update: Big Down Day in Biotech XBI down 3% Article to follow: big movers down CELG,KITE, PBYI, TSRO, XLRN etc Update-1… 5/8/17…Biotech Sector Losing Momentum XBI down 4.3% over 5 days although still up 15.5% YTD. IBB very weak today down over 2%. NASDAQ...
by Raynovich Rod | Apr 15, 2017 | Biopharmaceuticals
Update at Close…April 18 Biopharma takes a step back Healthcare stocks were top loser down 0.93%. Biotechs were hit hard today with many high fliers selling off. Large caps were all down with Regeneron (REGN) the big loser down 1.98%. The IBB was down 1% at...
by Raynovich Rod | Dec 8, 2016 | Biopharmaceuticals
Biotechs Unhinged-Roiled by Commentary and Tweet storms Biotech stocks rallied briefly early in the week but sold off abruptly over the past two days with a quote from Trump in a Time Person of the Year article as saying, “I’m going to bring down drug...
by Raynovich Rod | Jul 3, 2016 | Biopharmaceuticals
Biopharmaceutical Valuations Look Attractive Sector Poised for Rebound by Year End This is a continuing review of large cap biopharmaceutical valuation metrics to determine which companies can deliver growth from their broad pipelines. The biotech sector has...
by Raynovich Rod | May 31, 2016 | Biopharmaceuticals
Update June 1… After Close Biotech Holds…Uh oh CNBC is talking about biotech. IBB 281.18, XBI 58.18 This stealth rally has been going steady for two weeks but now CNBC and its “Fast Money” show are talking up biotech so is this a jinx? And...
by Raynovich Rod | May 27, 2016 | Biopharmaceuticals
Biotech Rally Fades after Five Days: IBB down 0.49%, XBI down 1% Biotech stocks were weak at the onset and could not come back but the sector is still up about 7% over five days. Stocks were mixed on thursday and healthcare was weak with the XLV flat at $70.84. The...
by Raynovich Rod | Mar 30, 2016 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Biopharmaceutical Portfolio Update- Biotechs with Upside Opportunity Caution No Rush to “Load Up” in a Bear Market Since Mid-January all of our previous portfolios were placed on hold and we recommended four new positions as long term holds. Here are...
by Raynovich Rod | Feb 22, 2016 | Biopharmaceuticals
2/23 After Close—Energy Rout Burns Biotech Stocks and NASDAQ The red screen dominated except few winners like ZIOPHARM Oncology (ZIOP) up 13.95% on a publication regarding gene editing. Another gene editing stock and recent IPO Editas Medicine (EDIT) was up...
by Raynovich Rod | Feb 16, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Rayno Large Cap Biopharmaceuticals…Part 2…A Stock pickers Market Time to Rebuild Your Portfolio: ABBV, BMY, GILD Below we have summarized selective metrics for large cap biopharmaceutical companies. We began the process of revising and rebalancing our...
by Raynovich Rod | Feb 10, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Have we reached a tradeable bottom in the biotech bear market? Today’s tape showed good volume but gains faded late in session. NASDAQ up 0.35% XLV up 0.88%-healthcare is the leading sector The biotech market bounced back early today in a broad rally...
